PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15625697-10	2005	Still in absence of PMSG-hCG, significant effect of treatment was only observed in COCs using the combination of CIL and rolipram (PDE3 and PDE4 inhibitor, respectively) compared to the use of IBMX.	cilostamide	113-116	phosphodiesterase 4A	Homo sapiens	140-144	
31176020-4	2019	Inhibiting each of the cAMP-hydrolyzing PDEs expressed in human endothelial cells revealed that phosphodiesterase 3 (PDE3) inhibition with cilostamide reduced angiogenic sprouting in vitro, while inhibitors of PDE2 and PDE4 family enzymes had no such effect.	cilostamide	139-150	phosphodiesterase 4A	Homo sapiens	219-223	
9105766-2	1997	Cilostamide, an antagonist of isozyme PDE3 and, to an even greater extent, in combination with rolipram, an antagonist of isozyme PDE4, markedly suppressed (delta = -60%; p < 0.01) the mitogenic proliferative response of lymphocytes in MLC to HLA-DR alloantigens from unrelated donors.	cilostamide	0-11	phosphodiesterase 4A	Homo sapiens	130-134	
33677066-10	2021	Cilostamide (300 nM) and rolipram (10 muM) were used to inhibit PDE3 and PDE4, respectively.	cilostamide	0-11	phosphodiesterase 4A	Homo sapiens	73-77	
32092149-5	2020	Selective inhibition of PDE3 and 4 with cilostamide and rolipram, respectively, revealed that in hiPSC-CM PDE4 was the predominant isoform for the regulation of ICa,L (cilostamide: +1.44 fold, 95% confidence interval: 1.26-1.64, n = 18; rolipram: +1.77 fold, 95% confidence interval: 1.50-2.09, n = 11).	cilostamide	168-179	phosphodiesterase 4A	Homo sapiens	106-110